Holland SD - Search Results

1

Porras AG, Holland SD, Gertz BJ. Porras AG, et al. Among authors: holland sd. Clin Pharmacokinet. 1999 May;36(5):315-28. doi: 10.2165/00003088-199936050-00002. Clin Pharmacokinet. 1999. PMID: 10384857 Review.

2

Montelukast dose selection in 6- to 14-year-olds: comparison of single-dose pharmacokinetics in children and adults.

Knorr B, Larson P, Nguyen HH, Holland S, Reiss TF, Chervinsky P, Blake K, van Nispen CH, Noonan G, Freeman A, Haesen R, Michiels N, Rogers JD, Amin RD, Zhao J, Xu X, Seidenberg BC, Gertz BJ, Spielberg S. Knorr B, et al. J Clin Pharmacol. 1999 Aug;39(8):786-93. doi: 10.1177/00912709922008434. J Clin Pharmacol. 1999. PMID: 10434229 Clinical Trial.

3

Studies of the oral bioavailability of alendronate.

Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow JC, Porras AG. Gertz BJ, et al. Among authors: holland sd. Clin Pharmacol Ther. 1995 Sep;58(3):288-98. doi: 10.1016/0009-9236(95)90245-7. Clin Pharmacol Ther. 1995. PMID: 7554702 Clinical Trial.

4

Clinical pharmacology of alendronate sodium.

Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. Gertz BJ, et al. Among authors: holland sd. Osteoporos Int. 1993;3 Suppl 3:S13-6. doi: 10.1007/BF01623002. Osteoporos Int. 1993. PMID: 8298197

5

Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.

Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MN, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG. Khan SA, et al. Among authors: holland sd. J Bone Miner Res. 1997 Oct;12(10):1700-7. doi: 10.1359/jbmr.1997.12.10.1700. J Bone Miner Res. 1997. PMID: 9333131 Free article. Clinical Trial.

6

Application of a new serum assay for type I collagen cross-linked N-telopeptides: assessment of diurnal changes in bone turnover with and without alendronate treatment.

Gertz BJ, Clemens JD, Holland SD, Yuan W, Greenspan S. Gertz BJ, et al. Among authors: holland sd. Calcif Tissue Int. 1998 Aug;63(2):102-6. doi: 10.1007/s002239900497. Calcif Tissue Int. 1998. PMID: 9685512 Clinical Trial.

7

Pharmacokinetics of intravenous alendronate.

Cocquyt V, Kline WF, Gertz BJ, Van Belle SJ, Holland SD, DeSmet M, Quan H, Vyas KP, Zhang KE, De Grève J, Porras AG. Cocquyt V, et al. Among authors: holland sd. J Clin Pharmacol. 1999 Apr;39(4):385-93. doi: 10.1177/00912709922007958. J Clin Pharmacol. 1999. PMID: 10197297 Clinical Trial.

8

Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.

Greenspan SL, Holland S, Maitland-Ramsey L, Poku M, Freeman A, Yuan W, Kher U, Gertz B. Greenspan SL, et al. Proc Assoc Am Physicians. 1996 May;108(3):230-8. Proc Assoc Am Physicians. 1996. PMID: 8774056 Clinical Trial.

9

Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.

Van Hecken A, Depré M, Verbesselt R, Wynants K, De Lepeleire I, Arnout J, Wong PH, Freeman A, Holland S, Gertz B, De Schepper PJ. Van Hecken A, et al. J Clin Pharmacol. 1999 May;39(5):495-500. J Clin Pharmacol. 1999. PMID: 10234597 Clinical Trial.

10

Effect of multiple doses of montelukast, a CysLT1 receptor antagonist, on digoxin pharmacokinetics in healthy volunteers.

Depré M, Van Hecken A, Verbesselt R, Wynants K, De Lepeleire I, Freeman A, Holland S, Shahane A, Gertz B, De Schepper PJ. Depré M, et al. J Clin Pharmacol. 1999 Sep;39(9):941-4. doi: 10.1177/00912709922008579. J Clin Pharmacol. 1999. PMID: 10471986 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47 results

Search Page

Filters